264 related articles for article (PubMed ID: 27465934)
1. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Ohshima Y; Kaira K; Yamaguchi A; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yokobori T; Miyazaki T; Asao T; Tsushima Y; Kuwano H; Ishioka NS
Cancer Sci; 2016 Oct; 107(10):1499-1505. PubMed ID: 27465934
[TBL] [Abstract][Full Text] [Related]
2. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
Wang Q; Tiffen J; Bailey CG; Lehman ML; Ritchie W; Fazli L; Metierre C; Feng YJ; Li E; Gleave M; Buchanan G; Nelson CC; Rasko JE; Holst J
J Natl Cancer Inst; 2013 Oct; 105(19):1463-73. PubMed ID: 24052624
[TBL] [Abstract][Full Text] [Related]
3. Differential expression and functional characterization of system L amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells.
Kim SG; Kim HH; Kim HK; Kim CH; Chun HS; Kanai Y; Endou H; Kim DK
Anticancer Res; 2006; 26(3A):1989-96. PubMed ID: 16827134
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Kaira K; Sunose Y; Ohshima Y; Ishioka NS; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Yamaguchi A; Segawa A; Ide M; Mori M; Oyama T; Takeyoshi I
BMC Cancer; 2013 Oct; 13():482. PubMed ID: 24131658
[TBL] [Abstract][Full Text] [Related]
5. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
[TBL] [Abstract][Full Text] [Related]
7. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Nagamori S; Promchan K; Nakajima T; Yamamoto N; Mori M; Kanai Y
Anticancer Res; 2010 Dec; 30(12):4819-28. PubMed ID: 21187458
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE
Pun IH; Chan D; Chan SH; Chung PY; Zhou YY; Law S; Lam AK; Chui CH; Chan AS; Lam KH; Tang JC
Cancer Res Treat; 2017 Jan; 49(1):219-229. PubMed ID: 27456944
[TBL] [Abstract][Full Text] [Related]
10. Characterization of amino acid transport system L in HTB-41 human salivary gland epidermoid carcinoma cells.
Park NS; Kim SG; Kim HK; Moon SY; Kim CS; Cho SH; Kanai Y; Endou H; Kim DK
Anticancer Res; 2008; 28(5A):2649-55. PubMed ID: 19035290
[TBL] [Abstract][Full Text] [Related]
11. Effects of bufalin on the mTOR/p70S6K pathway and apoptosis in esophageal squamous cell carcinoma in nude mice.
Liu Y; Wang X; Jia Y; Liu Y
Int J Mol Med; 2017 Aug; 40(2):357-366. PubMed ID: 28656204
[TBL] [Abstract][Full Text] [Related]
12. The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells.
Hsu HS; Lin MH; Jang YH; Kuo TT; Liu CC; Cheng TH
J Thorac Cardiovasc Surg; 2015 Jan; 149(1):378-85. PubMed ID: 25439783
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
Nishikawa T; Takaoka M; Ohara T; Tomono Y; Hao H; Bao X; Fukazawa T; Wang Z; Sakurama K; Fujiwara Y; Motoki T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Biol Ther; 2013 Mar; 14(3):230-6. PubMed ID: 23291985
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma.
Honjo H; Kaira K; Miyazaki T; Yokobori T; Kanai Y; Nagamori S; Oyama T; Asao T; Kuwano H
J Surg Oncol; 2016 Mar; 113(4):381-9. PubMed ID: 26936531
[TBL] [Abstract][Full Text] [Related]
15. Isoalantolactone Inhibits Esophageal Squamous Cell Carcinoma Growth Through Downregulation of MicroRNA-21 and Derepression of PDCD4.
Wen SW; Zhang YF; Li Y; Xu YZ; Li ZH; Lü H; Zhu YG; Liu ZX; Tian ZQ
Dig Dis Sci; 2018 Sep; 63(9):2285-2293. PubMed ID: 29781054
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone and Insulin-like growth factor-I (IGF-I) modulate the expression of L-type amino acid transporters in the muscles of spontaneous dwarf rats and L6 and C2C12 myocytes.
Sawa R; Nishida H; Yamamoto Y; Wake I; Kai N; Kikkawa U; Okimura Y
Growth Horm IGF Res; 2018; 42-43():66-73. PubMed ID: 30273774
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma.
Kim SH; Chau GC; Jang YH; Lee SI; Pyo S; Um SH
Hum Pathol; 2013 Feb; 44(2):226-36. PubMed ID: 22944293
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Kobayashi K; Ohnishi A; Promsuk J; Shimizu S; Kanai Y; Shiokawa Y; Nagane M
Neurosurgery; 2008 Feb; 62(2):493-503; discussion 503-4. PubMed ID: 18382329
[TBL] [Abstract][Full Text] [Related]
20. Berberine displays antitumor activity in esophageal cancer cells
Jiang SX; Qi B; Yao WJ; Gu CW; Wei XF; Zhao Y; Liu YZ; Zhao BS
World J Gastroenterol; 2017 Apr; 23(14):2511-2518. PubMed ID: 28465635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
